(Q34224527)

31 July 2017

1 reference

title

A means to an end: an overview of a hyperlipidemia outcomes management program (English)

1 reference

31 July 2017

1 reference

Patel B

1

1 reference

31 July 2017

Perez HE

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110 Suppl 6A

1 reference

31 July 2017

page(s)

12S-16S

1 reference

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

The American health care system--the movement for improved quality in health care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Prevention of coronary heart disease. Part I. Primary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Pharmacoeconomic considerations in the management of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Importance of quality measurement and improvement in pharmacy practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Cost effectiveness of risk reduction: the managed care perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

Lipid management: current diet and drug treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900673-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)00673-8

1 reference

31 July 2017

1 reference